Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody

Breast

Volumn 6, Issue 4, 1997, Pages 171-176

  Connor, A J M ^a   Pinder, S E ^a   Elston, C W ^a   Bell, J A ^a   Wencyk, P ^a   Robertson, J F R ^a   Blamey, R W ^a   Nicholson, R I ^a   Ellis, I O ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD VESSEL; BREAST CANCER; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LABELING INDEX; METASTASIS; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0030831589     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(97)90568-3     Document Type: Article

References (36)

1. Bloom H J, Richardson W W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
2. Verhoeven D, Bourgeois N, Derde M P, Kaufman L, Buyssens N. Comparison of cell growth in different parts of breast cancers. Histopathology 1990; 17: 505-509.
3. Baak J P. Mitosis counting in tumours. Hum Pathol 1990; 21: 683-685.
4. Meyers J S, Wittliff J L. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors. DNA ploidy. Int J Cancer 1991; 47: 213-220.
5. Kuenen-Boumeester V, Van Der Kwast T H, Van Laarhoven H A, Henzen-Logmans S C. Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol 1991; 44: 208-210.
6. Pavelic Z P, Pavelic L, Lower E E, Gapany S, Barker E A, Priesler H D. c-myc. c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma. Cancer Res 1992; 2597-2602.
7. Sasa M, Komaki K, Tsuzuki H et al. Tumor progression accompanied by increase in proliferation rate in breast cancer: a preliminary report. J Surg Oncol 1993; 54: 255-259.
8. Pence J C, Kilibash A L, Kerns B-J O, Marks J R. Iglehart J D. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol 1991; 48: 11-20.
9. Taylor H B, Norris H J. Well-differentiated carcinoma of the breast. Cancer 1970; 687-692.
10. Pinder S E, Ellis I O. Breast screening pathology. Surgery 1994: 12: 277-278.
11. Ellis I O, Galea M H, Locker A et al. Early experience in breast cancer screening: emphasis on development of protocols for triple assessment. The Breast 1993; 2: 148-153.
12. Duffy S W, Tabar L, Fagerberg G et al. Breast screening, prognostic factors and survival-results from the Swedish two county study. Br J Cancer 1991; 64: 1133-1138.
13. Cooper H S, Patchefsky A S, Krall R A. Tubular carcinoma of the breast. Cancer 1978; 42: 2334-2342.
14. Cattoretti G, Becker M H, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
15. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
16. Gerdes J, Lemke J, Baisch H, Walker H H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
17. Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403-410.
18. Ellis I O, Galea M, Broughton N, Locker A, Blamey R W, Elston C W. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992: 20: 479-489.
19. Pereira H, Pinder S E, Sibbering D M et al. Pathological prognostic factors in breast cancer IV. Should you be a typer or grader? A comparative study of two histological prognostic features in operable breast cancer. Histopathology 1995; 27: 219-226.
20. Pinder S E, Ellis I O, Galea M, O'Rourke S, Blamey R W, Elston C W. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24: 41-47.
21. Davis B W, Zava D T, Locher G W, Goldhirsch A, Hartman W H. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Br J Cancer Clin Oncol 1984; 20: 375-382.
22. Poulson H S, Jensen J, Hermansen C. Human breast cancer: heterogeneity of estrogen binding sites. Cancer 1981; 43: 1791.
23. Visscher D W, Shaheen C, Drozdowicz S, Crissman J D. Image cytophotometric DNA histogram heterogeneity in adenocarcinoma of the breast. Anal Quant Cytol Histol 1993; 15: 206-212.
24. Beerman H, Smit V T, Kluin P M, Bonsing B A, Hermans J, Cornelisse C J. Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 1991; 12: 147-154.
25. Pavelic Z P, Pavelic K, Carter C P, Pavelic L. Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol 1992; 118: 16-22.
26. Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Gariepy G. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1992; 23: 1388-1394.
27. Siitonen S M, Isola J J, Rantala I S, Helin H J. Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am J Clin Pathol 1993; 99: 226-231.
28. Going J J, Stanton P D, Cooke T G. Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labelled in vivo with bromodeoxyuridine. Am J Clin Pathol 1993; 100: 218-222.
29. Lee A K, Wiley B, Loda M et al. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992; 5: 61-67.
30. Barbareschi M, Girlando S, Mauri F M et al. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994; 102: 171-175.
31. Pinder S E, Wencyk P, Sibbering D M et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-149.
32. Weidner N, Moore D, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB1 antibody. Hum Pathol 1994; 25: 337-342.
33. Weidner N, Semple J P, Welch W R, Folkman J. Tumor angiogenesis and metastatis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
34. Verhoeven D, Van Marck E. Proliferation, basement membrane changes, metastasis and vascularization patterns in human breast cancer. Pathol Res Pract 1993; 189: 851-861.
35. Tsurusawa M, Fujimoto T. Cell cycle progression and phenotypic modification of Ki67 antigen-negative G1- and G2-phase cells in phorbol ester-treated Molt-4 human leukaemia cell. Cytometry 1995; 20: 146-153.
36. Couldwell W T, Weiss M H, Law R E, Hinton D R. Paradoxical elevation of Ki-67 labelling with protein kinase inhibition in malignant gliomas. J Neurosurg 1995; 82: 461-468.